Bioasis Technologies Inc. V.BTI

XB3 and its cost in the health care system?

[narmac]

Something I always planned on asking DrDR and have missed doing so,,,,is,,,Just what kind of costs are or will be asscitated with this technology?,,,,is there a reluctance from BP to get in waist deep because of the anticipated cost to produce the conjulates and or other. Is there an expected number or a target number if success is met and what might it look like. How much is reasonable in saving a life is an important discussion for all. It has always been in the back of my mind we will most likely be on the high end of the pricing scale in delivering our compounds to patients. Just thinking here.

[JDavenport]

My understanding, narmac, is that the manufacturing of a drug like xB3-001 using a genetically programmed cell line to produce fusion proteins, is not that much different than producing the Herceptin monoclonal antibody (mAb) without xB3. In a fusion protein, the xB3-Payload combination are produced in a unit by the cell line and that's why they're called fusion proteins.   

[narmac]

Thanks JD,,yes I would think that at commecialization we would reduce the over all costs substantially. It was just something which I thought of earlier but it kept escaping me when time came to discuss. It would ebawesome to have the team disuss some of these points ina presentation. Hope we start seeing some news being released on data points etc. My cupboard is also starting to suffer with

[JDavenport]

It was a good question, narmac. In earlier days Bioasis was dealing with chemical conjugates like BT2111 that was so successfully tested at Texas Tech. BT2111 was a combination of melanotransferrin (p97) and trastuzumab (with a linker between them, I believe). The conjugation was done by physically mixing the two with a linker in a container of some sort. Several chemical reactions and